Analyst Ratings for [GILD] Gilead Sciences, Inc.

3/4/25	Reiterated	Outperform	X
GILD Gilead Sciences Oppenheimer
$115 $132
2/18/25	Upgrades	Hold Buy	X
GILD Gilead Sciences Deutsche Bank
$120
2/13/25	Upgrades	Hold Buy	X
GILD Gilead Sciences DZ Bank
$108
1/10/25	Upgrades	Eq-Weight Overweight	X
GILD Gilead Sciences Morgan Stanley
$87 $113
12/10/24	Resumed	Buy	X
GILD Gilead Sciences BofA Securities
$109
11/15/24	Initiated	Outperform	X
GILD Gilead Sciences Wolfe Research
$110
11/14/24	Initiated	Buy	X
GILD Gilead Sciences Citigroup
$125
11/8/24	Downgrades	Buy Hold	X
GILD Gilead Sciences Maxim Group
10/21/24	Upgrades	Mkt Perform Outperform	X
GILD Gilead Sciences Leerink Partners
$74 $96
10/17/24	Initiated	Outperform	X
GILD Gilead Sciences Bernstein
$105
10/7/24	Upgrades	Eq Weight Overweight	X
GILD Gilead Sciences Wells Fargo
$78 $100
7/8/24	Upgrades	Mkt Perform Outperform	X
GILD Gilead Sciences Raymond James
$93
5/1/24	Reiterated	Buy	X
GILD Gilead Sciences Maxim Group
$90 $85
4/24/24	Upgrades	Reduce Hold	X
GILD Gilead Sciences HSBC Securities
$69
2/22/24	Downgrades	Buy Hold	X
GILD Gilead Sciences Truist
$91 $82
11/9/23	Initiated	Hold	X
GILD Gilead Sciences Deutsche Bank
$75
9/8/23	Upgrades	Neutral Buy	X
GILD Gilead Sciences BofA Securities
$88 $95
9/6/23	Initiated	Reduce	X
GILD Gilead Sciences HSBC Securities
$71
7/24/23	Reiterated	Equal Weight	X
GILD Gilead Sciences Barclays
$81 $80
5/16/23	Upgrades	Mkt Perform Outperform	X
GILD Gilead Sciences BMO Capital Markets
$90 $100
4/28/23	Resumed	Overweight	X
GILD Gilead Sciences Piper Sandler
$105
1/3/23	Downgrades	Outperform Sec Perform	X
GILD Gilead Sciences RBC Capital Mkts
$87
12/13/22	Resumed	Neutral	X
GILD Gilead Sciences BofA Securities
$85
12/9/22	Downgrades	Buy Hold	X
GILD Gilead Sciences DZ Bank
$90
10/31/22	Upgrades	Underweight Eq Weight	X
GILD Gilead Sciences Barclays
$60 $76
10/28/22	Reiterated	Market Perform	X
GILD Gilead Sciences BMO Capital Markets
$63 $72
10/28/22	Reiterated	Outperform	X
GILD Gilead Sciences Cowen
$75 $80
10/28/22	Reiterated	Buy	X
GILD Gilead Sciences Jefferies
$78 $86
10/28/22	Reiterated	Overweight	X
GILD Gilead Sciences JP Morgan
$80 $87
10/28/22	Upgrades	Neutral Overweight	X
GILD Gilead Sciences Piper Sandler
$79 $96
10/28/22	Reiterated	Outperform	X
GILD Gilead Sciences RBC Capital Mkts
$79 $82
10/28/22	Upgrades	Hold Buy	X
GILD Gilead Sciences Truist
$76 $91
10/28/22	Reiterated	Equal Weight	X
GILD Gilead Sciences Wells Fargo
$74 $75
10/4/22	Upgrades	Neutral Overweight	X
GILD Gilead Sciences JP Morgan
$72 $80
7/13/22	Initiated	Neutral	X
GILD Gilead Sciences Cantor Fitzgerald
$70
5/23/22	Initiated	Mkt Perform	X
GILD Gilead Sciences SVB Leerink
$68
2/2/22	Reiterated	Outperform	X
GILD Gilead Sciences BMO Capital Markets
$85 $75
2/2/22	Reiterated	Neutral	X
GILD Gilead Sciences BofA Securities
$73 $71
2/2/22	Reiterated	Outperform	X
GILD Gilead Sciences RBC Capital Mkts
$87 $85
2/2/22	Reiterated	Hold	X
GILD Gilead Sciences Truist
$77 $75
2/2/22	Reiterated	Equal Weight	X
GILD Gilead Sciences Wells Fargo
$72 $70
1/6/22	Downgrades	Overweight Eq-Weight	X
GILD Gilead Sciences Morgan Stanley
$84 $74
12/9/21	Resumed	Equal Weight	X
GILD Gilead Sciences Wells Fargo
$72
11/19/21	Upgrades	Mkt Perform Outperform	X
GILD Gilead Sciences BMO Capital Markets
$72 $85
11/19/21	Resumed	Neutral	X
GILD Gilead Sciences Piper Sandler
$77
10/20/21	Resumed	Outperform	X
GILD Gilead Sciences Cowen
7/30/21	Reiterated	Market Perform	X
GILD Gilead Sciences BMO Capital Markets
$67 $72
7/30/21	Reiterated	Outperform	X
GILD Gilead Sciences RBC Capital Mkts
$81 $84
4/1/21	Upgrades	Mkt Perform Outperform	X
GILD Gilead Sciences Bernstein
$80
3/30/21	Upgrades	Neutral Buy	X
GILD Gilead Sciences Redburn
1/19/21	Upgrades	Eq-Weight Overweight	X
GILD Gilead Sciences Morgan Stanley
$83
1/4/21	Upgrades	Neutral Buy	X
GILD Gilead Sciences Guggenheim
7/29/19	Upgrades	Outperform Top Pick	X
GILD Gilead Sciences RBC Capital Mkts
$91
7/15/19	Upgrades	Mkt Perform Outperform	X
GILD Gilead Sciences Wells Fargo
$68 $88
5/28/19	Downgrades	Neutral Sell	X
GILD Gilead Sciences Goldman
5/23/19	Upgrades	Neutral Buy	X
GILD Gilead Sciences Citigroup
5/21/19	Initiated	Neutral	X
GILD Gilead Sciences Credit Suisse
$70
4/26/19	Initiated	Outperform	X
GILD Gilead Sciences Bernstein
$82
4/10/19	Upgrades	Neutral Buy	X
GILD Gilead Sciences UBS
$75 $77
2/12/19	Downgrades	Buy Neutral	X
GILD Gilead Sciences Citigroup
$100 $75
2/12/19	Downgrades	Outperform Mkt Perform	X
GILD Gilead Sciences Wells Fargo
$95 $68
1/3/19	Upgrades	Perform Outperform	X
GILD Gilead Sciences Oppenheimer
$85
10/26/18	Reiterated	Overweight	X
GILD Gilead Sciences Barclays
$90 $95
10/26/18	Downgrades	Overweight Neutral	X
GILD Gilead Sciences Piper Jaffray
10/1/18	Initiated	Overweight	X
GILD Gilead Sciences Cantor Fitzgerald
$87
7/26/18	Downgrades	Outperform Neutral	X
GILD Gilead Sciences Robert W. Baird
$79
6/28/18	Initiated	Strong Buy	X
GILD Gilead Sciences Raymond James
5/2/18	Reiterated	Buy	X
GILD Gilead Sciences Maxim Group
$94 $89
3/6/18	Reiterated	Overweight	X
GILD Gilead Sciences Barclays
$90 $95
2/22/18	Reiterated	Mkt Perform	X
GILD Gilead Sciences Leerink Partners
$83 $80
2/12/18	Reiterated	Buy	X
GILD Gilead Sciences Mizuho
$83 $95
2/8/18	Reiterated	Buy	X
GILD Gilead Sciences Citigroup
$103 $105

GILD Gilead Sciences, Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.